<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691896</url>
  </required_header>
  <id_info>
    <org_study_id>501-1-13-15-16</org_study_id>
    <nct_id>NCT03691896</nct_id>
  </id_info>
  <brief_title>Calcium (ca),Phosphorus( P) and 25-hydroxyvitamin D(25OHD)] in Infants Born ≤ 32 PMA Gestational Weeks (GA)</brief_title>
  <acronym>Ca-P</acronym>
  <official_title>The Impact of the Dose of Vitamin D (vitD) on the Metabolism of ca, p and Concentrations of 25OHD, Bone Status and Development of Premature Infants up to 2 Years of Age. Prospective, Randomized, Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre of Postgraduate Medical Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre of Postgraduate Medical Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has not yet been established the optimal dose of vit. D for preterm infants in Poland. It
      is not known what dose of vit. D will provide the correct concentration of vit. D and the
      optimal development of the skeleton of the premature.

      The study will try to determine the optimal supplementation of vitamin D and the supply of Ca
      and P for normal growth and development of a child born prematurely.

      In addition, the investigators will evaluate any risk factors for deficiency and excess of
      vitamin D and the consequences of its deficiency and overdose. Simultaneously the study would
      make possible the determination of an optimal schedule for controlling the Ca-P levels in the
      group of the youngest infants born prematurely. In addition, the study will assess the
      relationship between maternal and newborn vitamin D resources right after birth, and the
      incidence of vitamin D deficiency in infants born prematurely. Preterm infants will be
      randomized in 3 groups assigned to different doses of vit. D. The study will investigate the
      metabolism of calcium, phosphorus, the health of bones and development of the premature
      babies till the age of 2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The participants of the study will be prematures, born ≤32 GA, hospitalized in the Department
      of Neonatology, in the neonatal intensive care unit. Hospitalized patients who meet the
      inclusion criteria will be randomized in 3 groups assigned to different doses of vit. D (400,
      800 or 1200 units(UNT) of vitamin D).

      At defined age points of postnatal life, parameters of calcium and phosphorus metabolism and
      vitamin D level will be tested, along with the health of bones, health status and
      development.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum 25OHD levels in cord blood in Polish preterm infants</measure>
    <time_frame>day of labour</time_frame>
    <description>assessment of 25OH D levels in children deficiency: &lt;10ng/ml, insufficient level: 10-30ng/ml, sufficient level: 30-50ng/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of supplementation of Vit. D during pregnancy on 25OHD serum level in Polish mothers</measure>
    <time_frame>day of labour</time_frame>
    <description>assessment of 25OH D levels in mothers deficiency: &lt;10ng/ml, insufficient level: 10-30ng/ml, sufficient level: 30-50ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of dosage of Vit D3 (400/800/1200 UNT per day) on serum 25OH D levels in preterm children</measure>
    <time_frame>4,8,12 weeks of life,1 and 2 years of age</time_frame>
    <description>assessment of serum 25OH D levels in children deficiency: &lt;10ng/ml, insufficient level: 10-30ng/ml, sufficient level: 30-50ng/ml; high level &gt; 60ng/ml, toxic level &gt; 100ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on Ca serum levels</measure>
    <time_frame>4,8,12 weeks of life,1 and 2 years of age</time_frame>
    <description>assessment of Ca serum levels in children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on P serum levels</measure>
    <time_frame>4,8,12 weeks of life,1 and 2 years of age</time_frame>
    <description>assessment of P serum levels in children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on urinary Ca excretion</measure>
    <time_frame>4,8,12 weeks of life,1 and 2 years of age</time_frame>
    <description>assessment of urinary calcium/creatinine index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of dosage of Vit D3 (400/800/1200 UNT /per day) on urinary P excretion</measure>
    <time_frame>4,8,12 weeks of life,1 and 2 years of age</time_frame>
    <description>assessment of urinary P/creatinine index (mg/mg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of total annual Vit D3 dose and bone calcification in children</measure>
    <time_frame>average of 1 and 2 years of age</time_frame>
    <description>assessment of bone status :Densitometry (DEXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation of cord blood 25OHD level and GA</measure>
    <time_frame>1st day of life</time_frame>
    <description>birth &lt;24 GA, 24-28GA, 28-32GA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of cord blood 25OHD level on birth weight</measure>
    <time_frame>1st day of life of age</time_frame>
    <description>assessment of percentile of birth weight (Fenton 2013) hypotrophy &lt;3p, eutrophy 3-97p, hypertrophy &gt;97p</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infant, Premature, Diseases</condition>
  <arm_group>
    <arm_group_label>Lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cholecalciferol 400UNT, oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cholecalciferol 800UNT, oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cholecalciferol 1200UNT, oral solution,</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol 400</intervention_name>
    <description>dose 400 UNT/day for 12 months</description>
    <arm_group_label>Lower dose</arm_group_label>
    <other_name>vit D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol 800</intervention_name>
    <description>dose 800 UNT/day for 12 months</description>
    <arm_group_label>Middle dose</arm_group_label>
    <other_name>vit D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol 1200</intervention_name>
    <description>dose 1200 UNT/day for 12 months</description>
    <arm_group_label>Higher dose</arm_group_label>
    <other_name>vit D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gestational age ≤32 weeks at birth

          -  hospitalization in the department no later than at the age of 7 days (for infants born
             outside the center)

          -  No birth defects or diseases permanently affecting the ability to accept enteral
             feeding

          -  Anticipated possibility of continuous monitoring of the course of treatment in
             hospital until discharge

          -  Consent of Parents / legal guardians for the participation in the study.

        Exclusion criteria

          -  gestational age&gt; 32 weeks at birth

          -  the beginning of hospitalization in the department later than the age of 7 days (for
             infants born outside the center)

          -  presence of congenital defects or diseases permanently affecting the ability to accept
             enteral feeding (e.g.oesophageal atresia, anal atresia, congenital umbilical hernia,
             gastroschisis, syndromes genetically determined)

          -  significant interruption (&gt; 1 week) of the hospitalization in the center

          -  lack of consent of the Parents / legal guardians to participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Weeks</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Zarlenga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mc postgraduate SPSK im prof.W.Orłowskiego Warszawa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Wilińska, DSc</last_name>
    <role>Study Chair</role>
    <affiliation>Mc postgraduate SPSK im prof.W.Orłowskiego Warszawa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ewa Głuszczak-Idziakowska, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mc postgraduate SPSK im prof.W.Orłowskiego Warszawa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magdalena Zarlenga, MD</last_name>
    <phone>+48224851171</phone>
    <email>magda.cmkp@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Wilińska, DSc</last_name>
    <phone>+48225841170</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SPSK im. prof. W.Orłowskiego CMKP Neonatology Departament</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-416</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Bodnar LM, Klebanoff MA, Gernand AD, Platt RW, Parks WT, Catov JM, Simhan HN. Maternal vitamin D status and spontaneous preterm birth by placental histology in the US Collaborative Perinatal Project. Am J Epidemiol. 2014 Jan 15;179(2):168-76. doi: 10.1093/aje/kwt237. Epub 2013 Oct 11.</citation>
    <PMID>24124195</PMID>
  </reference>
  <reference>
    <citation>Monangi N, Slaughter JL, Dawodu A, Smith C, Akinbi HT. Vitamin D status of early preterm infants and the effects of vitamin D intake during hospital stay. Arch Dis Child Fetal Neonatal Ed. 2014 Mar;99(2):F166-8. doi: 10.1136/archdischild-2013-303999. Epub 2013 Jul 13.</citation>
    <PMID>23852093</PMID>
  </reference>
  <reference>
    <citation>Natarajan CK, Sankar MJ, Agarwal R et al. Trial of Daily Vitamin D Supplementation in Preterm Infants. Pediatrics. 2014. http://dx.doi.org/10.1542/peds.2012-3395</citation>
  </reference>
  <reference>
    <citation>van de Lagemaat M, Rotteveel J, Schaafsma A, van Weissenbruch MM, Lafeber HN. Higher vitamin D intake in preterm infants fed an isocaloric, protein- and mineral-enriched postdischarge formula is associated with increased bone accretion. J Nutr. 2013 Sep;143(9):1439-44. doi: 10.3945/jn.113.178111. Epub 2013 Jul 31.</citation>
    <PMID>23902955</PMID>
  </reference>
  <reference>
    <citation>Schanler RJ, Burns PA, Abrams SA, Garza C. Bone mineralization outcomes in human milk-fed preterm infants. Pediatr Res. 1992 Jun;31(6):583-6.</citation>
    <PMID>1635820</PMID>
  </reference>
  <reference>
    <citation>Kislal FM, Dilmen U. Effect of different doses of vitamin D on osteocalcin and deoxypyridinoline in preterm infants. Pediatr Int. 2008 Apr;50(2):204-7. doi: 10.1111/j.1442-200X.2008.02553.x.</citation>
    <PMID>18353060</PMID>
  </reference>
  <reference>
    <citation>Christmann V, de Grauw AM, Visser R, Matthijsse RP, van Goudoever JB, van Heijst AF. Early postnatal calcium and phosphorus metabolism in preterm infants. J Pediatr Gastroenterol Nutr. 2014 Apr;58(4):398-403. doi: 10.1097/MPG.0000000000000251.</citation>
    <PMID>24253367</PMID>
  </reference>
  <reference>
    <citation>Backström MC, Mäki R, Kuusela AL, Sievänen H, Koivisto AM, Koskinen M, Ikonen RS, Mäki M. The long-term effect of early mineral, vitamin D, and breast milk intake on bone mineral status in 9- to 11-year-old children born prematurely. J Pediatr Gastroenterol Nutr. 1999 Nov;29(5):575-82.</citation>
    <PMID>10554126</PMID>
  </reference>
  <reference>
    <citation>Fewtrell MS, Prentice A, Jones SC, Bishop NJ, Stirling D, Buffenstein R, Lunt M, Cole TJ, Lucas A. Bone mineralization and turnover in preterm infants at 8-12 years of age: the effect of early diet. J Bone Miner Res. 1999 May;14(5):810-20.</citation>
    <PMID>10320530</PMID>
  </reference>
  <reference>
    <citation>McCarthy RA, McKenna MJ, Oyefeso O, Uduma O, Murray BF, Brady JJ, Kilbane MT, Murphy JF, Twomey A, O' Donnell CP, Murphy NP, Molloy EJ. Vitamin D nutritional status in preterm infants and response to supplementation. Br J Nutr. 2013 Jul 14;110(1):156-63. doi: 10.1017/S0007114512004722. Epub 2012 Nov 27.</citation>
    <PMID>23182428</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 18, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>September 28, 2018</last_update_submitted>
  <last_update_submitted_qc>September 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre of Postgraduate Medical Education</investigator_affiliation>
    <investigator_full_name>Maria Wilinska</investigator_full_name>
    <investigator_title>Head Of Neonatology</investigator_title>
  </responsible_party>
  <keyword>premature</keyword>
  <keyword>osteopenia</keyword>
  <keyword>Vit. D</keyword>
  <keyword>LBW (low birth weight)</keyword>
  <keyword>25OHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Infant, Premature, Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

